An enhanced chemotherapeutic effect facilitated by sonication of MSN

2017 ◽  
Vol 46 (35) ◽  
pp. 11875-11883 ◽  
Author(s):  
Yi Ding ◽  
Ziyi Song ◽  
Qian Liu ◽  
Shaohua Wei ◽  
Lin Zhou ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Therapeutic Modality ◽  
Sonodynamic Therapy ◽  
Non Invasive ◽  
Chemotherapeutic Effect

Sonodynamic therapy (SDT) is a non-invasive therapeutic modality for cancer treatment.

scholarly journals Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Zhenyu Ding ◽  
Qing Li ◽  
Rui Zhang ◽  
Li Xie ◽  
Yang Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dendritic Cell ◽  
Cancer Treatment ◽  
Checkpoint Inhibitors ◽  
Rapid Development ◽  
Therapeutic Modality ◽  
Advanced Lung Cancer ◽  
Cell Vaccine ◽  
Lung Cancer Treatment ◽  
Dc Vaccine

AbstractNeoantigens are considered to be ultimate target of tumor immunotherapy due to their high tumor specificity and immunogenicity. Dendritic cell (DCs) vaccines based on neoantigens have exciting effects in treatment of some malignant tumors and are a promising therapeutic modality. Lung cancer is a lethal disease with the highest morbidity and mortality rate in the world. Despite the rapid development of targeted therapy and immune checkpoint inhibitors for lung cancer in recent years, their efficacy is still unsatisfactory overall. Therefore, there is an urgent unmet clinical need for lung cancer treatment. Here, we attempted to treat lung cancer using a personalized neoantigen peptide-pulsed autologous DC vaccine and conducted a single-arm, 2 medical centers, pilot study initiated by the investigator (ChiCTR-ONC-16009100, NCT02956551). The patients enrolled were patients with heavily treated metastatic lung cancer. Candidate neoantigens were derived from whole-exome sequencing and RNA sequencing of fresh biopsy tissues as well as bioinformatics analysis. A total of 12 patients were enrolled in this study. A total of 85 vaccine treatments were administered with a median value of 5 doses/person (range: 3–14 doses/person). In total, 12–30 peptide-based neoantigens were selected for each patient. All treatment-related adverse events were grade 1–2 and there were no delays in dosing due to toxic effects. The objective effectiveness rate was 25%; the disease control rate was 75%; the median progression-free survival was 5.5 months and the median overall survival was 7.9 months. This study provides new evidence for neoantigen vaccine therapy and new therapeutic opportunities for lung cancer treatment.

Sonodynamic Therapy: Concept, Mechanism and Application to Cancer Treatment

2016 ◽  
pp. 429-450 ◽  
Author(s):  
Anthony P. McHale ◽  
John F. Callan ◽  
Nikolitsa Nomikou ◽  
Colin Fowley ◽  
Bridgeen Callan
Keyword(s):  
Cancer Treatment ◽  
Sonodynamic Therapy

P04.22 Tumor treating fields in high-grade glioma patients: A retrospective single-center study

2021 ◽  
Vol 23 (Supplement_2) ◽  
pp. ii23-ii23
Author(s):  
R Lucaciu ◽  
B Suchorska ◽  
M Wettig ◽  
S Jung ◽  
M Scholz
Keyword(s):  
Promoter Methylation ◽  
Daily Life ◽  
Methylation Status ◽  
Mgmt Promoter Methylation ◽  
Therapeutic Modality ◽  
High Grade ◽  
Newly Diagnosed ◽  
Non Invasive ◽  
Tumor Treating Fields ◽  
Mgmt Promoter

Abstract BACKGROUND Tumor-treating fields (TTFields) are a modern anti-mitotic, non-invasive therapy for the treatment of patients with recurrent and newly diagnosed glioblastoma multiforme (GBM). In Europe, Optune® recieved in 2015 the CE certification. TTFields are a low-intensity (1–3 V/cm) approved therapeutic modality using a non-invasive application of intermediate frequency (200 kHz) alternating electric fields through four transducer arrays directly applied to the skin. The EF-14 study has shown that the addition of TTFields to temozolomide chemotherapy in patients with newly diagnosed GBM significantly improved overall survival (OS) and progression-free survival (PFS) without additional adverse events, apart from mild to moderate skin irritations (Stupp et al., JAMA 2017). MATERIAL We retrospectively analyzed data from TTFields-treated patients (2015–2020) that were treated at our department. Patient characteristics such as MGMT promoter methylation status, age, and diagnosis, as well as treatment duration and TTFields therapy usage, were evaluated for this study. RESULTS 29 patients were treated with TTFields therapy between 2015 and 2020 at our hospital. Most patients received TTFields as primary treatment together with temozolomide maintenance therapy. In detail, 48% of patients were diagnosed with newly diagnosed GBM, 41% received TTFields therapy after tumor recurrence and 10% were diagnosed with other high-grade gliomas. In summary, patients could integrate TTFields therapy into their daily life and showed high adherence to the therapy.Particularly, one of our patients (with MGMT-promoter methylation positive) receives TTFields therapy now for almost 1229 days (approx. 41 months) and is still on therapy. Additionally, this patient shows a high usage rate of 86% indicating well integration of the therapy into daily life. CONCLUSION Taken together, our data provided the outcomes of using TTFields together with chemotherapy in the treatment of recurrent and newly diagnosed GBM in our department. Therapy with TTFields has been showing to provide significant clinical benefit for GBM patients.

scholarly journals 13-gene DNA Methylation Analysis from Oral Brushing: A Promising Non Invasive Tool in the Follow-up of Oral Cancer Patients

2019 ◽  
Vol 8 (12) ◽  
pp. 2107 ◽  
Author(s):  
Davide B. Gissi ◽  
Achille Tarsitano ◽  
Andrea Gabusi ◽  
Roberto Rossi ◽  
Giuseppe Attardo ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Oral Cancer ◽  
Cancer Treatment ◽  
Sample Collection ◽  
Methylation Analysis ◽  
Non Invasive ◽  
Locoregional Relapse ◽  
Positive Score ◽  
Dna Methylation Analysis

Background: This study aimed to evaluate the prognostic value of a non-invasive sampling procedure based on 13-gene DNA methylation analysis in the follow-up of patients previously treated for oral squamous cell carcinoma (OSCC). Methods: The study population included 49 consecutive patients treated for OSCC. Oral brushing sample collection was performed at two different times: before any cancer treatment in the tumor mass and during patient follow-up almost 6 months after OSCC treatment, within the regenerative area after OSCC resection. Each sample was considered positive or negative in relation to a predefined cut-off value. Results: Before any cancer treatment, 47/49 specimens exceeded the score and were considered as positive. Six months after OSCC resection, 16/49 specimens also had positive scores in the samples collected from the regenerative area. During the follow-up period, 7/49 patients developed locoregional relapse: 6/7 patients had a positive score in the regenerative area after OSCC resection. The presence of a positive score after oral cancer treatment was the most powerful variable related to the appearance of locoregional relapse. Conclusion: 13-gene DNA methylation analysis by oral brushing may have a clinical application as a prognostic non-invasive tool in the follow-up of patients surgically treated for OSCC.

scholarly journals Pulmonary Delivery of Biological Drugs

Pharmaceutics ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 1025
Author(s):  
Wanling Liang ◽  
Harry W. Pan ◽  
Driton Vllasaliu ◽  
Jenny K. W. Lam
Keyword(s):  
Pulmonary Delivery ◽  
High Specificity ◽  
Therapeutic Modality ◽  
Systemic Delivery ◽  
Biological Drugs ◽  
Onset Of Action ◽  
Non Invasive ◽  
Inhalation Devices ◽  
Rapid Absorption ◽  
Immense Potential

In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery. The main challenges in the formulation and inhalation devices are discussed, together with the possible strategies that can be applied to address these challenges. Current clinical developments in inhaled biological drugs for both local and systemic applications are also discussed to provide an insight for further research.

scholarly journals AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor–Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment

2016 ◽  
Vol 76 (11) ◽  
pp. 3295-3306 ◽  
Author(s):  
Natalie A. Daurio ◽  
Stephen W. Tuttle ◽  
Andrew J. Worth ◽  
Ethan Y. Song ◽  
Julianne M. Davis ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Cancer Treatment ◽  
Metabolic Reprogramming ◽  
Therapeutic Modality ◽  
Ampk Activation

scholarly journals Magnetic nanofibers based bandage for skin cancer treatment: a non‐invasive hyperthermia therapy

2020 ◽  
Vol 3 (6) ◽  
Author(s):  
Kaushik Suneet ◽  
Tamasa De ◽  
Annapoorni Rangarajan ◽  
Shilpee Jain
Keyword(s):  
Skin Cancer ◽  
Cancer Treatment ◽  
Non Invasive ◽  
Hyperthermia Therapy ◽  
Magnetic Nanofibers
Sign in / Sign up

Export Citation Format

Share Document